Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 5/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | UBE2N | P61088 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | TAS2R8 | Q9NYW2 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13879516 | 0.89 | KDM4E (0.47) | MAPTKDM4EGAACYP1A2CYP3A4 | |
| SCHEMBL13879434 | 0.87 | NPSR1 (0.46) | MAPTKDM4EGAACYP1A2CYP3A4 | |
| SCHEMBL11398860 | 0.84 | GAA (0.74) | MAPTKDM4EGAACYP1A2CYP3A4 | |
| SCHEMBL14584233 | 0.83 | MAPT (0.81) | MAPTKDM4EGAACYP1A2CYP3A4 | |
| SCHEMBL13879575 | 0.82 | KDM4E (0.42) | MAPTKDM4EGAACYP1A2CYP3A4 | |
| SCHEMBL13879373 | 0.81 | KDM4E (0.42) | MAPTKDM4EGAACYP1A2CYP3A4 | |
| SCHEMBL13879573 | 0.80 | GAA (0.78) | MAPTKDM4EGAACYP1A2CYP3A4 | |
| SCHEMBL13879408 | 0.80 | HDAC6 (0.59) | MAPTGAAALDH1A1L3MBTL1 | |
| SCHEMBL13879505 | 0.79 | HCRTR1 (0.44) | MAPTKDM4E | |
| SCHEMBL13879556 | 0.76 | TAS2R8 (0.48) | MAPTKDM4EALDH1A1TAS2R8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. | 2009-04-16 | — | — | US | disclosed |
| WO-2007047146-A2 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, RTF2 | MAPT 4203/4885KDM4E 797/4885GAA 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.